Roughly one in six Omani sickle cell patients has silent liver damage worth screening for.
Said A. Al-Busafi, Fatma Al-Zaabi, and Salam Al-Kindi
Screening over 2,200 Omani patients with sickle cell disease, researchers found that about 17% had sickle cell hepatopathy, a complication significantly more common in younger, male patients and linked to gallstones, prior blood transfusions, and markers of red blood cell breakdown. No single factor emerged as an independent predictor once other variables were accounted for. The findings argue for proactive liver screening as a routine part of sickle cell disease care in the Gulf region.
- The question: How common is silent liver damage in sickle cell disease?
- The study: Researchers screened more than 2,200 Omani patients with sickle cell disease.
- The finding: About 17% had sickle cell hepatopathy — more common in younger, male patients.
- The nuance: It was linked to gallstones, prior blood transfusions, and markers of red blood cell breakdown. But no single factor was an independent predictor.
Takeaway: proactive liver screening should be a routine part of sickle cell disease care in the Gulf region.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.